Journal: Journal of Clinical Investigation

Article Title: CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion

doi: 10.1172/jci125336

Figure Lengend Snippet: Figure 8. Expression levels of CCL28, CCR10, or RARβ are closely associated with overall survival in 117 patients with OSCC. (A) Representative images of IHC staining of CCL28, CCR3, CCR10, and RARβ in normal oral mucosa and OSCC tissues. Scale bars: 100 μm. Magnified images of the boxed area are shown in the insets. Scale bars: 20 μm. (B) Frequency of histoscores in normal oral mucosa and OSCC tissues. (C) Kaplan-Meier survival curve of patients with OSCC stratified based on CCL28, CCR3, CCR10, or RARβ expres- sion by the log-rank test.

Article Snippet: CCL28, RANKL, or OPG levels in cell culture media were measured with commercially available kits for CCL28 (BioLegend), RANKL (EIAab), or OPG (Boster) according to the manufacturer’s instructions.

Techniques: Expressing, Immunohistochemistry

Journal: The Prostate

Article Title: The identification of a novel antibody for CD133 using human antibody phage display

doi: 10.1002/pros.23656

Figure Lengend Snippet: Case study of a patient with aggressive prostate cancer. A, CT scan of diffuse liver metastases that appeared in the presence of declining PSA after the patient failed treatment with Zytiga (abiraterone). B, Strong staining for CD133 was detected in the liver metastases using HA10. C, No staining for the AR was observed in the liver metastases using an antibody specific to the N-terminal domain of the AR. This antibody would detect both full-length AR and AR splice variants. D, Staining was observed for the neuroendocrine differentiation marker chromogranin A in the liver metastases. E, An original TURP specimen from the patient depicting poorly differentiated Gleason 4 + 5 cancer stained for CD133. Note the complete absence of CD133. F, Liver biopsy from the patient after failing treatment with carboplatin and taxotere documenting moderate staining for CD133. Scale bars, (B-D) 200 μm and (E-F) 60 μm. [Color figure can be viewed at wileyonlinelibrary.com]

Article Snippet: The following primary antibodies and concentrations used were: CD133 HA10 antibody, rabbit monoclonal (1:100); androgen receptor SP107 (Sigma), rabbit monoclonal (1:200); chromogranin A PB9097 (Boster Biological Technology) rabbit polyclonal (1:1000); CD133/1 (AC133) (Miltenyi) mouse monoclonal (1:25).

Techniques: Computed Tomography, Staining, Marker

Journal: Translational Lung Cancer Research

Article Title: Targeting complement C5a to improve radiotherapy sensitivity in non-small cell lung cancer

doi: 10.21037/tlcr-23-258

Figure Lengend Snippet: Infiltration of recruited CD8 + T cells increased after treatment of RT. (A) Mice were inoculated subcutaneously with LLC tumor cells and treated with 8 Gy of local RT daily for 3 times. Tumor tissues were collected at the indicated time points for subsequent analysis. (B) Tumor tissues in RT and control groups. (C) Immunofluorescence of tumors in RT and control groups. Sections were stained with an antibody recognizing CD8 (green) and DAPI (blue). Scale bars represent 50 µm. Representative images are shown. (D) Flow cytometry assays displayed that infiltration of CD8 + T cells were upregulated after RT. RT, radiotherapy; DAPI, 4',6-diamidino-2-phenylindole; FSC-A, forward scatter-A; FITC-A, fluorescein isothiocyanate-A; LLC, Lewis lung carcinoma; con, control.

Article Snippet: After processes of dewaxing, rehydration, and antigen retrieval with ethylenediaminetetraacetic acid (EDTA) antigen retrieval buffer (pH 8.0) (Servicebio, Wuhan, China; G1206), the slides were then blocked with blocking solution [PBS with 10% fetal calf serum (FCS) and 0.1% TritonX] at room temperature for 1 hour, then washed in PBS and incubated overnight at 4 oC in the appropriate primary anti-C5aR antibody (Abcam, 1:500) and anti-CD8a antibody (Boster, 1:50) diluted in blocking solution.

Techniques: Control, Immunofluorescence, Staining, Flow Cytometry

Journal: Translational Lung Cancer Research

Article Title: Targeting complement C5a to improve radiotherapy sensitivity in non-small cell lung cancer

doi: 10.21037/tlcr-23-258

Figure Lengend Snippet: RT upregulated C5aR1 expression in RT-recruited CD8 + T cells. (A) CD8 + T cells were sorted by magnetic beads for RNA-seq. (B) RNA-seq analysis was displayed and the differential genes are shown in the heat map. (C) DEG counts in RT and control groups. (D) Top 20 of GO enrichment of the up-regulated genes. The red arrows indicate that these functional pathways exist C5aR1 gene enrichment. (E) Volcano map of RNA-seq showing the DEGs. The red dots indicate significantly upregulated genes. RNA-seq, RNA sequencing; RT, radiotherapy; DEGs, differentially expressed genes; GO, Gene Ontology.

Article Snippet: After processes of dewaxing, rehydration, and antigen retrieval with ethylenediaminetetraacetic acid (EDTA) antigen retrieval buffer (pH 8.0) (Servicebio, Wuhan, China; G1206), the slides were then blocked with blocking solution [PBS with 10% fetal calf serum (FCS) and 0.1% TritonX] at room temperature for 1 hour, then washed in PBS and incubated overnight at 4 oC in the appropriate primary anti-C5aR antibody (Abcam, 1:500) and anti-CD8a antibody (Boster, 1:50) diluted in blocking solution.

Techniques: Expressing, Magnetic Beads, RNA Sequencing, Control, Functional Assay